The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 291.50
Bid: 293.50
Ask: 295.00
Change: -10.50 (-3.48%)
Spread: 1.50 (0.511%)
Open: 300.00
High: 304.00
Low: 291.50
Prev. Close: 302.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Trading Update

21 Apr 2021 07:00

RNS Number : 0778W
Synthomer PLC
21 April 2021
 

 

21st April 2021

 

Synthomer plc

 

Q1 Trading Update

 

Stronger underlying trading across all divisions and continued exceptional Nitrile Latex performance

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the quarter ended 31st March 2021.

 

Strong trading momentum across all businesses

 

Performance Elastomers

 

Performance Elastomers has continued to perform strongly. The positive trends experienced in our Nitrile Latex business during 2020 have continued through the first quarter of 2021 with overall performance ahead of expectations. Both volumes and unit margins were significantly ahead of prior year driven by exceptional demand as a consequence of the COVID-19 pandemic.

 

Conditions in our SBR latex business also continued to improve, with all segments except paper trading ahead of the comparative period in 2020. Following the strategic review of the European SBR network we completed the consultation in Marl (Germany) and the planned closure of the Oulu (Finland) site at the end of Q1.

 

Functional Solutions

 

Functional Solutions has seen a sustained improvement in the first quarter of 2021. Our consumer facing and industrial end markets have remained robust with our Oil and Gas business improving month on month. Volumes and unit margins were ahead of the comparative period supported by the acquisition of and synergies from OMNOVA and the introduction of low cost capacity in Europe and the US to drive organic growth in differentiated applications.

 

Industrial Specialities and Acrylate Monomers

 

Industrial Specialities also had a good start to the year with activity levels and unit margins significantly ahead of prior year in all major segments including automotive and consumer facing markets. Acrylate Monomers likewise benefitted from improved demand and industry supply issues resulting in a significant uplift in profitability.

 

Reducing Leverage

 

The strong trading performance and cash generation has resulted in a further reduction in proforma net debt:EBITDA to 1.2x at 31st March 2021 with anticipated leverage of less than 1.0x expected by 30th June 2021 (31st December 2020: 1.8x).

 

 

Positive outlook: strong trading increases FY EBITDA expectations

 

Whilst macroeconomic conditions remain uncertain given the ongoing COVID-19 pandemic, we are encouraged by a further strengthening of underlying trading conditions and the strong performances across all our divisions during Q1.

 

Accordingly, the Board now expects 2021 EBITDA to be in excess of £450m reflecting a further rise in the one off profitability of our Nitrile Latex business and the strengthening of the underlying trading conditions. Our expectation that the Nitrile Latex business will return to more normalised levels in 2022 remains unchanged.

 

Conference call

The company will hold a conference call for investors and analysts at 0800 BST today:

 

Dial in number:

UK (Toll free) 0800 640 6441

UK (Local) 020 3936 2999

United States (Local) 1 646 664 1960

All other locations +44 20 3936 2999

 

Access code: 921802

 

 

-ENDS-

 

Further information:

 

Calum MacLean, Chief Executive Officer

Steve Bennett, Chief Financial Officer Tel: +44 1279 436211

Tim Hughes, President, Corporate Development

 

Charles Armitstead/ Matt Denham, Teneo Tel: +44 7703 330 269/ +44 7825 735596

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTIMMATMTTTBAB
Date   Source Headline
30th Jul 20197:00 amRNSResults of Rights Issue
26th Jul 20192:48 pmRNSDirector/PDMR Shareholding
26th Jul 20192:46 pmRNSDirector/PDMR Shareholding
24th Jul 20194:34 pmRNSDirector Declaration
15th Jul 20197:00 amRNSAdmission of Nil Paid Rights
10th Jul 20191:49 pmRNSPublication of Circular and Prospectus
10th Jul 20191:34 pmRNSDirector/PDMR Shareholding
3rd Jul 20197:00 amRNSAcquisition
2nd Jul 20193:56 pmRNSDirector Declaration
13th Jun 201911:18 amRNSDirector Declaration
25th Apr 20194:45 pmRNSResult of AGM
25th Apr 20197:00 amRNSQ1 Trading Update
10th Apr 20194:51 pmRNSDirector/PDMR Shareholding
10th Apr 20194:50 pmRNSDirector/PDMR Shareholding
10th Apr 20194:43 pmRNSDirector/PDMR Shareholding
10th Apr 20194:41 pmRNSDirector/PDMR Shareholding
28th Mar 20193:51 pmRNSDirector/PDMR Shareholding
28th Mar 20193:50 pmRNSDirector/PDMR Shareholding
25th Mar 20193:15 pmRNSAnnual Financial Report
21st Mar 20193:39 pmRNSDirector Declaration
18th Mar 201910:02 amRNSDirector/PDMR Shareholding
12th Mar 201911:25 amRNSDirector/PDMR Shareholding
12th Mar 201911:23 amRNSDirector/PDMR Shareholding
5th Mar 20194:09 pmRNSDirector/PDMR Shareholding
4th Mar 20197:00 amRNSResults for the year ended 31 December 2018
1st Mar 20193:26 pmRNSDirector Declaration
3rd Dec 201810:54 amRNSHolding(s) in Company
9th Nov 201811:36 amRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSQ3 Trading update
17th Oct 20189:29 amRNSDirector Declaration
21st Sep 20189:17 amRNSDirectorate Change
6th Aug 20187:00 amRNSResults for the six months ended 30 June 2018
11th Jul 20186:25 pmRNSDirector/PDMR Shareholding
10th Jul 20189:47 amRNSHolding(s) in Company
4th Jul 201811:45 amRNSHolding(s) in Company
4th Jul 201811:44 amRNSHolding(s) in Company
4th Jul 201811:43 amRNSHolding(s) in Company
28th Jun 20183:12 pmRNSUpdate on Proposed Offering
25th Jun 20187:19 amRNSPROPOSED OFFERING OF EUR300M BOND & REFINANCING
21st Jun 201810:16 amRNSResult of Extraordinary General Meeting
8th Jun 20187:00 amRNSEuropean Commission investigation
4th Jun 20181:02 pmRNSNotice of GM
3rd May 20181:38 pmRNSHolding(s) in Company
2nd May 20184:29 pmRNSDirector/PDMR Shareholding
26th Apr 20182:23 pmRNSResult of AGM
26th Apr 20187:00 amRNSQ1 Trading update
9th Apr 20184:54 pmRNSDirector Declaration
27th Mar 20181:03 pmRNSDirector/PDMR Shareholding
27th Mar 20181:01 pmRNSDirector/PDMR Shareholding
26th Mar 20184:55 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.